AI Can Help Track MS Progression
Medically reviewed by Drugs.com.
By Dennis Thompson HealthDay Reporter
MONDAY, May 19, 2025 — Artificial intelligence (AI) can help detect when a person’s multiple sclerosis (MS) has reached an advanced state, a new study says.
A newly developed AI correctly judged with 90% accuracy when a person’s MS had transitioned to a stage where it will progress steadily, researchers reported recently in the journal npj Digital Medicine.
“For patients, this means that the diagnosis can be made earlier, which makes it possible to adjust the patient’s treatment in time and slow down the progression of the disease,” study co-author Kim Kultima, an associate professor of medical sciences and clinical chemistry at Uppsala University in Sweden, said in a news release.
Most MS patients start with the relapsing-remitting form of the disease, where deterioration occurs between periods of stability.
Over time, many then transition to secondary progressive MS, where their symptoms get steadily worse with no breaks.
It’s important to detect this transition because the two forms of MS require different treatments, researchers said in background notes.
However, this diagnosis is currently made an average three years after the transition has begun, leading some patients to take medicine that’s no longer effective, researchers said.
They trained the new AI model using clinical data from more than 22,000 patients in the Swedish MS Registry, including neurological tests, MRI scans and ongoing treatments.
“By recognizing patterns from previous patients, the model can determine whether a patient has the relapsing-remitting form or whether the disease has transitioned to secondary progressive MS,” Kultima said.
“What is unique about the model is that it also indicates how confident it is in each individual assessment,” he added. “This means that the doctor will know how reliable the conclusion is and how confident the AI is in its assessment.”
In a test dataset of about 3,600 patients, the AI detected their transition between early to progressive MS in a timely fashion — or even earlier — about 87% of the time, researchers found.
“In the long term, the model could also be used to identify suitable participants for clinical trials – which could contribute to more effective and individualized treatment strategies,” Kultima said.
The team has placed an open version of the AI model on the internet, for other researchers to test.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-20 00:00
Read more

- Alzheimer’s Drug Can Be Safely Administered In Memory Clinics, Study Says
- Landmark Women's Health Study Saved From Funding Cuts
- Combined Flu, SARS-CoV-2 Vaccine as Effective as Individual Vaccines for Older Adults
- Ready-Made Immune Therapy Effective Against Leukemia
- Risk Factors for Alzheimer Disease Linked to Cognitive Function Before Midlife
- U.S. Illicit Opioid Use Could Be 20 Times Higher Than Previously Estimated
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions